Switch theme
Sign up to access all valuation multiples
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
2017
483
LTM Revenue $59.4M
LTM EBITDA -$423M
$527M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Beam Therapeutics has a last 12-month revenue (LTM) of $59.4M and a last 12-month EBITDA of -$423M.
In the most recent fiscal year, Beam Therapeutics achieved revenue of $63.5M and an EBITDA of -$384M.
Beam Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Beam Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $59.4M | XXX | $63.5M | XXX | XXX | XXX |
| Gross Profit | $59.0M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 99% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$423M | XXX | -$384M | XXX | XXX | XXX |
| EBITDA Margin | -712% | XXX | -605% | XXX | XXX | XXX |
| EBIT | -$428M | XXX | -$416M | XXX | XXX | XXX |
| EBIT Margin | -720% | XXX | -654% | XXX | XXX | XXX |
| Net Profit | -$396M | XXX | -$377M | XXX | XXX | XXX |
| Net Margin | -666% | XXX | -593% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Beam Therapeutics's stock price is $16.
Beam Therapeutics has current market cap of $1.6B, and EV of $527M.
See Beam Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $527M | $1.6B | XXX | XXX | XXX | XXX | $-4.60 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Beam Therapeutics has market cap of $1.6B and EV of $527M.
Beam Therapeutics's trades at 8.3x EV/Revenue multiple, and -1.4x EV/EBITDA.
Equity research analysts estimate Beam Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Beam Therapeutics has a P/E ratio of -4.0x.
See valuation multiples for Beam Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.6B | XXX | $1.6B | XXX | XXX | XXX |
| EV (current) | $527M | XXX | $527M | XXX | XXX | XXX |
| EV/Revenue | 8.9x | XXX | 8.3x | XXX | XXX | XXX |
| EV/EBITDA | -1.2x | XXX | -1.4x | XXX | XXX | XXX |
| EV/EBIT | -1.2x | XXX | -1.3x | XXX | XXX | XXX |
| EV/Gross Profit | 8.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | -4.0x | XXX | -4.2x | XXX | XXX | XXX |
| EV/FCF | -1.5x | XXX | -1.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBeam Therapeutics's last 12 month revenue growth is -10%
Beam Therapeutics's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $1.0M for the same period.
Beam Therapeutics's rule of 40 is -52% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Beam Therapeutics's rule of X is -738% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Beam Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -10% | XXX | -9% | XXX | XXX | XXX |
| EBITDA Margin | -712% | XXX | -605% | XXX | XXX | XXX |
| EBITDA Growth | 11% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -52% | XXX | -615% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -738% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 579% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 754% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Beam Therapeutics acquired XXX companies to date.
Last acquisition by Beam Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Beam Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Beam Therapeutics founded? | Beam Therapeutics was founded in 2017. |
| Where is Beam Therapeutics headquartered? | Beam Therapeutics is headquartered in United States of America. |
| How many employees does Beam Therapeutics have? | As of today, Beam Therapeutics has 483 employees. |
| Who is the CEO of Beam Therapeutics? | Beam Therapeutics's CEO is Mr. John Evans. |
| Is Beam Therapeutics publicy listed? | Yes, Beam Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Beam Therapeutics? | Beam Therapeutics trades under BEAM ticker. |
| When did Beam Therapeutics go public? | Beam Therapeutics went public in 2020. |
| Who are competitors of Beam Therapeutics? | Similar companies to Beam Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Beam Therapeutics? | Beam Therapeutics's current market cap is $1.6B |
| What is the current revenue of Beam Therapeutics? | Beam Therapeutics's last 12 months revenue is $59.4M. |
| What is the current revenue growth of Beam Therapeutics? | Beam Therapeutics revenue growth (NTM/LTM) is -10%. |
| What is the current EV/Revenue multiple of Beam Therapeutics? | Current revenue multiple of Beam Therapeutics is 8.9x. |
| Is Beam Therapeutics profitable? | Yes, Beam Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Beam Therapeutics? | Beam Therapeutics's last 12 months EBITDA is -$423M. |
| What is Beam Therapeutics's EBITDA margin? | Beam Therapeutics's last 12 months EBITDA margin is -712%. |
| What is the current EV/EBITDA multiple of Beam Therapeutics? | Current EBITDA multiple of Beam Therapeutics is -1.2x. |
| What is the current FCF of Beam Therapeutics? | Beam Therapeutics's last 12 months FCF is -$355M. |
| What is Beam Therapeutics's FCF margin? | Beam Therapeutics's last 12 months FCF margin is -598%. |
| What is the current EV/FCF multiple of Beam Therapeutics? | Current FCF multiple of Beam Therapeutics is -1.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
